Regeneron Pharmaceuticals Inc
REGN
NASDAQ
Biotechnology
$803.48
USD
-2.49 (-0.31%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $82.16B
Volume 424.5K
Revenue
$15.53B
TTM
+9.3%
YoY
Gross Margin
85%
TTM
-0.8%
YoY
Net Income
$4.33B
TTM
-2.9%
YoY
Operating Cash Flow
$4.68B
TTM
-1.3%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 3,675.6 | 3,754.3 | 3,884.3 | 3,605.4 | 4,290.7 |
YoY Growth | +3.6% | +0.9% | +2.5% | +19.0% | +16.7% |
Cost of Revenue | 530.2 | 521.6 | 584.6 | 669.4 | 576.5 |
Gross Profit | 3,145.4 | 3,232.7 | 3,299.7 | 2,936.0 | 3,714.2 |
Selling, General & Administrative | 634.2 | 657.8 | 775.0 | 647.7 | 662.1 |
Other Operating Expenses | 0.0 | -10.0 | 10.0 | 0.0 | 0.0 |
Total Operating Expenses | 2,065.9 | 2,205.9 | 2,429.8 | 2,293.1 | 2,420.7 |
Operating Income | 1,079.5 | 1,026.8 | 869.9 | 642.9 | 1,293.5 |
EBITDA | 1,214.6 | 1,163.5 | 1,014.9 | 766.1 | 1,417.2 |
Other Income / Expense | 442.8 | 755.8 | 186.0 | 201.2 | 245.3 |
Total Other Income / Expense | 439.2 | 736.5 | 173.8 | 188.3 | 234.3 |
Income Before Income Taxes | 1,518.7 | 1,763.3 | 1,043.7 | 831.2 | 1,527.8 |
Income Taxes | 127.1 | 303.3 | 199.1 | 104.0 | 230.9 |
Net Income | 1,391.6 | 1,460.0 | 844.6 | 727.2 | 1,296.9 |
Consolidated Net Income / Loss | 1,391.6 | 1,460.0 | 844.6 | 727.2 | 1,296.9 |
Net Income Attributable to Common Shareholders | 1,391.6 | 1,460.0 | 844.6 | 727.2 | 1,296.9 |
Basic EPS | $13.24 | $14.09 | $8.20 | $6.99 | $12.62 |
Diluted EPS | $12.81 | $13.62 | $7.86 | $6.75 | $12.23 |
Basic Shares Outstanding | 105.1M | 103.6M | 103.0M | 104.0M | 102.8M |
Diluted Shares Outstanding | 108.6M | 107.2M | 107.4M | 107.7M | 106.0M |